Antitrust police raid Sanofi's Hungarian HQ; Glaxo nabs FDA approval for OTC Flonase;

> Hungary's competition watchdog raided Sanofi's ($SNY) domestic headquarters as part of a probe into its wholesaler-selection practices. Report

> The FDA approved an over-the-counter version of Flonase, the allergy-fighting nasal spray from GlaxoSmithKline ($GSK); a launch is planned for next year. Report

> GlaxoSmithKline ($GSK) rolled out its once-weekly Type 2 diabetes treatment Tanzeum (albiglutide), a GLP-1 agonist, in the U.S. Release

> Ranbaxy Laboratories signed up to market Cipher Pharmaceuticals' acne drug Absorica (irotretinoin) in Brazil. Report

> CANbridge Life Sciences inked a marketing partnership with Jazz Pharmaceuticals ($JAZZ) to commercialize the oral mucositis treatment Caphosol in China. Release

> Novo Nordisk ($NVO) signed on to help feed needy families in Egypt during the holy month of Ramadan. Report

> Bayer and Amgen ($AMGN) said their cancer drug Nexavar failed to hit its primary endpoint in another Phase III breast cancer study. Report

And Finally... Want a custom bobblehead for your promo campaign? Amazon now has a 3D printing store. Report

Suggested Articles

Eli Lilly bought full-page ads in more than a dozen newspapers in the U.S. to let people with diabetes who use Lilly drugs to know help is available.

Only months after a game-changing new approval for Vascepa, Amarin has lost a key fight over its patents—and now it's scrambling to respond.

Move over, Roche. There’s a new small cell lung cancer therapy on the scene, and it belongs to AstraZeneca.